Jazz Pharmaceuticals plc (JAZZ)


Stock Price Forecast

April 18, 2024


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Jazz Pharmaceuticals plc chart...

About the Company

Jazz Pharmaceuticals plc (a merger of Jazz Pharmaceuticals, Inc. and Azur Pharma plc) is an American biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003. One of the company's considerable products is the United States Food and Drug Administration (FDA) approved drug Xyrem (sodium oxybate), the sodium salt of the naturally occurring neurotransmitter γ-Hydroxybutyric acid (GHB). In 2017, net product sales of Xyrem were $1.187 billion, which represented 74% of the company's total net product sales. In 2019, Jazz was granted FDA-approval to market Sunosi with indications for treating excessive daytime sleepiness (EDS) in narcolepsy as well as obstructive sleep apnea (OSA). In 2022, it was announced that Axsome Therapeutics would be acquiring Sunosi from Jazz Pharmaceuticals In 2007, the company pled guilty to felony charges related to its illegal marketing of Xyrem for off-label use. The company is also a member of the Pharmaceutical Research and Manufacturers of America (PhRMA).

Sector

Life Sciences

Industry

Pharmaceutical Preparations

Employees

3199

Exchange

Nasdaq

$444M

Total Revenue

3K

Employees

$7B

Market Capitalization

21.86

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $JAZZ News

Jazz Pharmaceuticals: Targeting The Low-Hanging Fruit In Oncology Might Pay Off

4d ago, source:

Jazz Pharmaceuticals' successful commercial products have shown increasing adoption and sales revenues. See why I rate JAZZ ...

Avadel Pharmaceuticals plc (AVDL)

2d ago, source: Yahoo Finance

The rally in global equities extended into Asia on July 3, buoyed by positive momentum from […] Jazz Pharmaceuticals plc (NASDAQ: JAZZ) has filed suit against the FDA for approving Avadel ...

Jazz Pharmaceuticals plc (NASDAQ: JAZZ) - Share Price and Research

9d ago, source: Intelligent Investor

What is the current share price of Jazz Pharmaceuticals plc (JAZZ)? Jazz Pharmaceuticals plc's (JAZZ) current share price is $114.00. This constitutes a price movement of 4.18% when compared to the ...

Optimistic Outlook on Jazz Pharmaceuticals’ Zanidatamab Across Multiple Cancer Types: A Buy Rating Analysis

1mon ago, source: Business Insider

Jazz Pharmaceuticals (JAZZ) Company Description: Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization ...

Jazz Pharmaceuticals plc (JAZZ)

3d ago, source: Yahoo Finance

Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected ...

Jazz Pharmaceuticals PLC

5d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Jazz Pharmaceuticals PLC

5d ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Jazz Pharmaceuticals PLC

22d ago, source: Barron's

Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...